Fresenius Kabi Launches its Idacio (adalimumab, biosimilar) in Germany

Shots:

• The launch of Idacio is based on its MAA approval by EC for all indications of the reference product in therapy areas of rheumatology, dermatology and gastroenterology
• The approval by EC follows EMA’s recommendation of product based on P-III study results assessing PK, safety, and immunogenicity with the reference product
• Idacio is a mAb TNF inhibitor, targeted for autoimmune disorders, is available in pre-filled syringe, pre-filled pen and vial presentations. AbbVie and Fresenius Kabi collaborated to commercialize Idacio with its expected launch in September 2023

Click here to read full press release/ article | Ref: Fresenius Kabi| Image: Mississauga News